About > News

Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of Monoclonal Antibody Therapies

Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of Monoclonal Antibody Therapies Names BJ Bormann as new CEO Rotterdam and Cambridge, Massachusetts – July 24, 2013 — Harbour Antibodies BV, the creator of transgenic mice to aid in the discovery of new human antibody-based therapies, has raised €2.5M ($3.3M) to continue R&D and commercialize its technologies.  The round was led by Atlas Venture.  With the funding, pharma executive BJ Bormann, Ph.D. has been named as CEO.  Bormann’s previous positions have included SVP of Business Development and Licensing at Boehringer Ingelheim and VP of Strategic Alliances at Pfizer.  Atlas Venture’s Peter Barrett will join the Board of Directors as …

ShangPharma and Harbour Antibodies Announce Licensing Agreement

ShangPharma and Harbour Antibodies Announce Licensing Agreement SHANGHAI, Sept. 13, 2012 /PRNewswire/ — ShangPharma Corporation (NYSE: SHP) (“ShangPharma” or the “Company”), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Harbour Antibodies (“Harbour”), a Dutch biotechnology company, today announced that they have entered into a collaborative licensing agreement under which ShangPharma will develop therapeutic antibody candidates for its customers using Harbour’s transgenic mouse-based fully human antibody development technology. Harbour will provide ShangPharma with human immunoglobulin-gene transgenic mice for use at the Company’s Shanghai facility, where researchers will provide fully human antibody development services to ShangPharma’s pharmaceutical clients. The Harbour transgenic mice licensed under the agreement produce H2L2 …

Harbour Antibodies signs agreement with Lilly

Harbour Antibodies signs agreement with Lilly Agreement aimed at validating a transgenic mouse platform for the generation of human antibodies Harbour Antibodies BV, an Erasmus MC spin-off company announced today the completion of a non-exclusive research and licence agreement with Eli Lilly and Company (“Lilly”), a global pharmaceutical company, to generate and develop human therapeutic antibodies comprising immunoglobulin heavy and light chains (H2L2) using one of Harbour’s transgenic mouse antibody discovery platforms. Under the terms of the agreement Harbour will receive an upfront payment, success-based fees, and potential downstream product milestones and royalties. Specific financial terms were not disclosed. “We are delighted to partner with Lilly,” said Professor Frank Grosveld, …

Harbour News

Upcoming Events

Contact Us

Name: 
Email: 
Company: 
Message: 
Submit

Join Mailing List

Name: 
Email: 
Company: 
Submit